Vascular endothelial cells are a target for blood-borne pathogens which may affect their integrity and thromboresistant properties. Here, we report that cultured bovine and human endothelial cells lose their thromboresistance following interaction with the avian hemangioma-inducing retrovirus. We show that the envelope (env) gene product, glycoprotein 85, is responsible for this effect, which appears soon after infection without viral replication or cell transformation. Induction of thrombogenicity is associated with a reduction in prostacyclin release and increased expression of tissue factor. These observations may explain the occurrence of thrombosis frequently observed in association with the hemangiosarcomas induced by avian hemangiomainducing retrovirus. These unique endothelial cell-virus interactions may also be a model for the pathogenesis of various vascular diseases.
Endothelial cells (EC) provide a nonthrombogenic surface and act as a selective barrier between the blood and the vessel wall. Injury to the endothelium may promote thrombosis and, under certain conditions, cause disseminated intravascular coagulation or contribute to the formation of atheromatous lesions (4, 17) . Certain bacteria may cause significant vascular damage either by invasion through the endothelium or by the deleterious effects of endotoxin (4, 14) . Viruses may also affect the vascular endothelium. However, with the exception of the diseases caused by arboviruses (dengue and Junin viruses), which are associated with severe vascular damage manifested by hemorrhagic syndromes, other viruses cause only subtle perturbation of the EC (11, 12) . Viral proteins, viral particles, and virus-related nucleic acids of measles virus, rubella virus, herpes simplex virus, cytomegalovirus, human immunodeficiency virus, and other viruses have been detected within EC and/or smooth muscle cells taken from artherosclerotic lesions (1, 3, 4) . It has been proposed that subclinical viral infections which affect EC are among the inciting agents leading to the development of vessel disease (1, 3) .
Infection of cultured EC with viruses often alters highly specialized endothelial functions such as adherence of granulocytes, production of colony-stimulating factors and interferon, synthesis of matrix proteins, induction of C3 and Fc receptors, and increased thrombogenicity (4, 7, 8, 15) . All these effects appear to depend on viral replication or cellular transformation.
We have recently isolated a new field strain of avian leukosis virus from spontaneous hemangiosarcomas of layer hens. This newly isolated avian hemangioma retrovirus (AHV) induces tumors in about 30% of birds inoculated on the day of hatching (6) (Fig. 1A) . In this system, BAEC treated with AHV no longer prevented platelet aggregation 5 h posttreatment, prior to any apparent cell damage (Fig. 1C ). This change in BAEC behavior is unique to AHV, since the exposure of BAEC to RAV type 1 (RAV-1), another member of the avian leukosis virus group whose genomic sequences are closely related to those of AHV, was not thrombogenic (Fig. 1B) .
We constructed two recombinant viruses in order to determine whether AHV glycoproteins were responsible for the effect on BAEC. Treatment of EC with recombinant virus RxAHV1, a RAV-1 which contains the AHV env, caused platelet aggregation around the EC (Fig. 1E ). This effect was not seen with AxHRV5, a recombinant virus expressing the RAV-1 env gene (Fig. 1F) .
Since the effect of AHV on BAEC was observed as early as 5 h postinfection, we suggest that virus replication was not involved. This was confirmed by demonstrating that UV-inactivated AHV is still effective in abolishing the antiaggregating effect of EC (Fig. 1D) . It is known that mammalian cells are not permissive for most avian sarcomaleukemia viruses, none of which can propagate in those cells (2, 13) . On the other hand, vesicular stomatitis virus (VSV), which replicates and destroys cultured BAEC, did not impair the capacity of EC to prevent platelet aggregation in the ECM system (Fig. 1G ). (10) . Figure 1 shows that the occurrence of platelet 0 r-_ es v o^<aggregation adjacent to perturbed EC is associated with ('t nX>@ t6 _°J * =sDlower PGI2 production. (Isolation of SU was carried out by mild treatment of purified virions with Triton X-100, followed by extraction with butanol, as previously described [16] .) The observation (Fig. 2 ) that treated cells release higher amounts of PGI2 into culture media 20 h posttreatment is explained by the progressive cytopathic effect of AHV on these cells (16) . EC damage is associated with activation of the arachidonic cascade and the release of PGI2 (18) . The amount of PGI2
secreted from VSV-infected BAEC was unchanged at 30, 60, and 180 min postinfection. However, beginning at 5 h postinfection, the cells started to release increased amounts of PGI2. At 24 h, the amount released was fivefold higher than that of the uninfected cells. VSV-induced cell killing on these cultures started 6 h postinfection (data not shown).
It is of interest that the treatment of EC with lipopolysaccharide (LPS) is also associated with impaired release of PGI2 during the first 4 h (Fig. 2) . The RxAHV1 recombinant virus containing the AHV env gene was as inhibitory to PGI2 secretion as AHV (Fig. 1) , while incubation of bovine EC with RAV-1 or with the reciprocal recombinant virus AxHRVS did not impair PGI2 secretion. These results confirm the hypothesis that the AHV SU is responsible for the observed alterations in the capacity of EC to release PGI2.
Perturbation of EC function can also be accompanied by the expression of membrane tissue factor (TF) activity. Quiescent EC do not express this factor, whereas its activity may be induced by molecules such as interleukin-1, LPS, and tumor necrosis factor. We determined, therefore, whether AHV SU also enhances TF expression by a method based on the production of procoagulant activity (5). The levels of TF expressed by BAEC treated with AHV and by BAEC treated with RxAHV1 recombinant virus were 60-and 140-fold higher, respectively, than that expressed by untreated cells. Human EC treated with partially purified AHV glycoproteins expressed about a 100-fold increase in TF. In contrast, treatment with RAV-1 or AxHRV5 recombinant virus did not increase TF. The induction of TF was rapid but transient, lasting less than 20 h after treatment. EC treated with VSV and LPS showed elevated amounts of TF which lasted only for 8 h (Fig. 3) .
The effects of AHV and its glycoproteins on EC cultures are probably operative in the pathogenesis of AHV disease in chickens. The vascular tumors produced by AHV are associated with the presence of large thrombi formed around and within the lesions (Soffer et al., in press). These avian hemangiosarcomas are composed of EC whose surfaces have apparently become thrombogenic. Unfortunately, avian EC are as yet impossible to cultivate, so the direct effect of AHV and its glycoproteins on EC thromboresistance cannot be evaluated.
Hemangiosarcoma has been studied recently in two experimental models. these tumors induced hemangiosarcoma by recruiting cells of the recipients as early as 1 to 3 days posttransplantation (19) . It seems likely that the initiating agents in both models stimulate the production and secretion of growth factors or chemotactic factors responsible for tumor formation or both.
We show here that AHV glycoprotein perturbs EC, causing reduced secretion of PGI2, increased expression of TF activity, and high expression of interleukin-1 (ResnickRoguel et al., unpublished results). It is clear from this study that the EC perturbation, as well as the cytopathic effects, is caused by the AHV envelope glycoprotein. These glycoproteins may also play a role in the induction of hemangioma and other endothelium-related vascular diseases.
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